CHINA’S CLOVER BIOPHARMA VACCINE PARTNERSHIP WITH GSK COMES TO AN END

• China's Clover Biopharmaceuticals said on Monday it has ended its joint venture with GlaxoSmithKline Plc. GSK.L to develop a COVID-19 vaccine using the British drug maker's adjuvant, even as early-stage trials showed good results.
• The decision marks a further upset to G...

Phase 1 SCB-313 for Malignant Pleural Effusion Treatment tested by Clover Biopharmaceuticals in Australia

According to an announcement by an international biotechnology company in China, Clover Biopharmaceuticals, thriving to develop new biological therapies, the first-ever cancer patient suffering from malignant pleural effusions was admitted in Australia in a fully human TRAIL-Trimer fusion protein...

Australia: Clover Biopharmaceuticals tests Phase 1 study of SCB-313 for Malignant Pleural Effusion

CHENGDU, China ( November 21, 2019 ) Clover Biopharmaceuticals, an international clinical-stage biotechnology company based on the development of novel and revelatory biological therapies, announced today that the very first patient was administered in Australia for the treatment of cancer patien...

First Patient Dosed in Phase I Study of SCB-313 for MPE by Clover Biopharmaceuticals

International clinical-stage biotechnology engaged in generating new and transformative biologic treatments, Clover Biopharmaceuticals publicized today how they had dosed their first patient in a Phase I trial of SCB-313 in Australia for treating cancer patients having malignant pleural effusions...